Solid Biosciences (SLDB) Upgraded to Buy by ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Solid Biosciences (NASDAQ:SLDB) from a hold rating to a buy rating in a research note released on Tuesday.

Several other analysts have also commented on the stock. Chardan Capital restated a buy rating and set a $15.00 price target on shares of Solid Biosciences in a research report on Thursday, February 7th. Svb Leerink lowered shares of Solid Biosciences from an outperform rating to a market perform rating in a research report on Friday, February 8th. Citigroup upgraded shares of Solid Biosciences from a sell rating to a neutral rating and set a $8.00 price target on the stock in a research report on Friday, February 8th. BTIG Research assumed coverage on shares of Solid Biosciences in a research report on Monday, December 10th. They issued a neutral rating on the stock. Finally, Leerink Swann lowered shares of Solid Biosciences from an outperform rating to a market perform rating in a research report on Thursday, February 7th. Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $29.38.

SLDB stock opened at $10.55 on Tuesday. The company has a current ratio of 10.31, a quick ratio of 10.31 and a debt-to-equity ratio of 0.01. Solid Biosciences has a one year low of $5.97 and a one year high of $54.84.

In other news, COO Pedro Alvaro Amorrortu sold 9,000 shares of the firm’s stock in a transaction dated Friday, January 4th. The shares were sold at an average price of $30.07, for a total value of $270,630.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Matthew Bennett Arnold sold 5,000 shares of the firm’s stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $30.08, for a total transaction of $150,400.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,000 shares of company stock worth $581,030.

Large investors have recently bought and sold shares of the company. Flinton Capital Management LLC purchased a new position in shares of Solid Biosciences in the fourth quarter worth about $47,000. Legal & General Group Plc lifted its stake in shares of Solid Biosciences by 47.8% in the third quarter. Legal & General Group Plc now owns 1,825 shares of the company’s stock worth $86,000 after buying an additional 590 shares in the last quarter. First Manhattan Co. lifted its stake in shares of Solid Biosciences by 100.0% in the fourth quarter. First Manhattan Co. now owns 2,000 shares of the company’s stock worth $53,000 after buying an additional 1,000 shares in the last quarter. Great West Life Assurance Co. Can purchased a new position in shares of Solid Biosciences in the fourth quarter worth about $83,000. Finally, Metropolitan Life Insurance Co. NY lifted its stake in shares of Solid Biosciences by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 4,160 shares of the company’s stock worth $111,000 after buying an additional 3,249 shares in the last quarter. 68.27% of the stock is currently owned by hedge funds and other institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation.

Featured Story: Correction

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

M Holdings Securities Inc. Invests $1.61 Million in Consolidated Edison, Inc.  Stock
M Holdings Securities Inc. Invests $1.61 Million in Consolidated Edison, Inc. Stock
Micron Technology, Inc.  Holdings Cut by First Dallas Securities Inc.
Micron Technology, Inc. Holdings Cut by First Dallas Securities Inc.
Exxon Mobil Co.  Holdings Lowered by First Dallas Securities Inc.
Exxon Mobil Co. Holdings Lowered by First Dallas Securities Inc.
United Technologies Co.  Shares Bought by M Holdings Securities Inc.
United Technologies Co. Shares Bought by M Holdings Securities Inc.
Insider Buying: Golden Star Resources Ltd.  Senior Officer Acquires 5,000 Shares of Stock
Insider Buying: Golden Star Resources Ltd. Senior Officer Acquires 5,000 Shares of Stock
$48.21 Million in Sales Expected for Lovesac Co  This Quarter
$48.21 Million in Sales Expected for Lovesac Co This Quarter


© 2006-2019 Ticker Report